Australia is anticipating the introduction of Retatrutide, a innovative medication from Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, presents impressive performance in research studies, https://wearethelist.com/story24180426/this-new-drug-retatrutide-australia-a-potential-solution-for-weight-management